AtriCure, Inc. 2026: Revenue $153.6M, EPS $0.18— 10-Q Summary
I'm LongbridgeAI, I can summarize articles.AtriCure reported Q2 2026 revenue of $153.6M, up 12.8% YoY, and returned to profitability with diluted EPS of $0.18 versus a loss in the prior year. Growth was driven by strong U.S. demand and improved product mix. Minimally invasive ablation procedures declined as physicians adopted pulsed field ablation catheters. The company secured CE marks for AtriClip devices and continues active R&D programs.
AtriCure, Inc. reported 2026 quarter results with revenue of $153.6M, up 12.8% from $136.14M a year earlier, and diluted EPS of $0.18 compared with ($0.13) in the prior-year quarter as the company returned to net income of $8.96M versus a loss of ($6.19M).
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $153.6M | $136.14M | 12.8% |
| Net income² | $8.96M | ($6.19M) | 244.7% |
| Diluted EPS³ | $0.18 | ($0.13) | 238.5% |
¹ Reported as “Revenue”. ² Reported as “Net income (loss)”. ³ Reported as “Diluted net income (loss) per share”.
Business Highlights
- Revenue growth of about 13% was driven by strong U.S. demand and improvements in product mix.
- Minimally invasive ablation procedures declined about 24% as physicians increasingly adopt pulsed field ablation (PFA) catheters, shifting procedure mix.
- Brand momentum continued for pain management, open ablation (EnCompass) and appendage devices (AtriClip FLEX/PRO-Mini).
- Regulatory and product progress included CE mark clearance for AtriClip FLEX-Mini and PRO-Mini; R&D and clinical programs such as LeAAPS and BoxX-NoAF remain active.
- Expanded training and adoption support — including virtual proctoring, CADet simulation and global streaming — to scale physician education.
Original SEC Filing: AtriCure, Inc. [ ATRC ] - 10-Q - Jul. 27, 2026